Mark Goldstone

Mark Goldstone is a Partner at Eckuity, a venture investor in early stage Health Tech and has over 25 years of experience in the healthcare industry, encompassing operations, commercialization, consulting, M&A and Venture Capital. He has led some of the largest specialist consulting and communications groups in the world and was a founding partner at Forepont Capital (VC).

He was COO of EuroRSCG Life (now Havas), Global CEO of healthcare at top brand and business consultancy, Interbrand and Worldwide President of Doyle, Dane and Bernbach global healthcare businesses.

Mark has executed numerous venture investments, M&A, financing and strategic partnership transactions for a broad array of early stage, middle market and emerging growth companies in technology, life sciences and healthcare services. He has developed successful commercialization strategies and programs from early-stage and market development, to product launch and late-stage lifecycle management for blue-chip pharmaceutical and packaged goods companies including Pfizer, Merck, Novartis, Bayer, GSK, Sanofi, Colgate Palmolive, L’Oreal, Danone, Johnson & Johnson, Roche. In fact, Mark has worked on seven of the world’s top-selling medicines.

Mark began his career as a clinical Pharmacist and is a member of the Royal Pharmaceutical Society. He is Board member of the prestigious Galien Foundation and the Industry Advisory Board for the UK Government’s BRCD initiative.